Zoledronic Acid (Zometa): FDA Approval, Licensing in Türkiye, and Reimbursement Status

• FDA Approval: Yes (first approval date: August 20, 2001)
• Trade Name: Zometa
• Active Ingredient: Zoledronic acid
• Administration: Intravenous injection (into a vein)
• Class: Bisphosphonate
• Category: Chemotherapeutic agent / Antineoplastic
• Manufacturer: Novartis Pharmaceuticals Corporation
• Distribution in Türkiye: Licensed and distributed by Novartis and various generic companies
• Cancers for Which It Is Approved:  Multiple myeloma, bone metastases from solid tumors (such as breast, prostate, or lung cancer), and hypercalcemia (cancer-related high calcium levels)

What Is Zometa and How Does It Work?

Zometa contains zoledronic acid. It is used particularly to slow or prevent deterioration of bone structure, generally to treat problems caused by tumors that have spread to bone (bone metastases). It is also used in some circumstances to reduce high blood calcium. It is administered intravenously.

How Does It Work?

Zometa belongs to the bisphosphonate class. These medicines reduce the activity of osteoclasts, the cells responsible for bone breakdown. By suppressing these cells, Zometa slows bone resorption and preserves bone structure.

It also controls excessive calcium release caused by bone metastases. Zometa therefore helps maintain bone strength and prevent some serious complications of cancer in bone.

FDA (United States Food and Drug Administration) Approval History

• August 20, 2001: Treatment of hypercalcemia of malignancy (cancer-related high calcium levels).
• February 22, 2002: Prevention of skeletal-related events, such as pathological fractures and spinal cord compression, caused by multiple myeloma and bone metastases from solid tumors.
• April 17, 2007: Approved in the United States for Paget's disease of bone.
• August 20, 2007: Approved for postmenopausal osteoporosis treatment.
• June 5, 2008: Approved to prevent fractures due to bone fragility after hip fracture.
• June 1, 2009: Approved to prevent postmenopausal osteoporosis.

Licensing in Türkiye

Zometa was licensed in Türkiye on December 27, 2001.

Therapeutic Indications

Used to prevent skeletal complications—pathological fracture, spinal cord compression, radiotherapy, surgery to bone, or hypercalcemia—in patients with multiple myeloma and radiologically demonstrated lytic lesions, and patients with advanced cancer and bone metastases. Also used to treat hypercalcemia of malignancy.

Is Zometa Reimbursed?

Zometa (zoledronic acid) is reimbursed by SGK (Social Security Institution) in Türkiye under certain conditions.

• SGK covers Zometa when used to prevent skeletal-related events, such as pathological fractures or spinal cord compression, in patients with cancer and bone metastases. However, the medical report must explicitly document bone metastases.
• Use of Zometa for cancer-related high blood calcium is also considered within reimbursement coverage.

Price: Zometa 4 mg, 1 vial: 3579.90 TL

Mechanisms of Resistance

• Reactivation of osteoclasts: Zometa suppresses osteoclasts, but these cells may reactivate over time in some patients, limiting long-term effects. Increased osteoclast numbers or function may produce treatment resistance.
• Retention in bone and reduced availability: Zometa acts by binding to bone. Over time, excessive binding may prevent release of active drug in a form that can act on cells, reducing osteoclast suppression and causing resistance.
• Changes in cellular transport and uptake: Osteoclast uptake of Zometa depends on intracellular transport systems. Genetic or structural changes in these systems may reduce cellular uptake and effectiveness.
• Changes in intracellular targets: Zometa targets the mevalonate pathway in osteoclasts, disrupting protein synthesis. Structural changes in pathway enzymes or activation of alternative pathways may make blockade more difficult.
• Changes in the bone microenvironment: Tumor cells can remodel the bone microenvironment. Cytokines and growth factors may help osteoclasts escape drug suppression. Local pH changes or intercellular signaling pathways may also reduce the drug's effect.

Absorption

Zometa is not taken orally; it is given only by intravenous infusion. There is therefore no conventional absorption process. The entire dose enters the circulation directly and begins acting rapidly. Oral administration is not used because gastrointestinal absorption would be inadequate.

Distribution

After entering the bloodstream, a substantial proportion of Zometa binds to bone, accumulating particularly where bone breakdown is active because osteoclasts are its target. Drug not bound to bone is rapidly eliminated through the kidneys.

Zometa has low plasma protein binding, leaving a high proportion unbound in blood and enabling rapid action. Entry into brain tissue is very limited, so central nervous system effects are not expected.

Metabolism

Zometa is not metabolized by conventional liver enzymes. Its chemical structure is highly stable and undergoes no biological transformation. It therefore remains in its original form and continues acting. This metabolically inactive structure allows prolonged retention in bone. However, while prolonging effects, it may also increase the burden on the kidneys. Kidney function must therefore be monitored closely throughout treatment.

Dose Range

• Hypercalcemia of malignancy (cancer-related high calcium): A single 4 mg intravenous infusion over at least 15 minutes. Ensure adequate hydration before and after treatment.
• Prevention of skeletal-related events from bone metastases: A 4 mg intravenous infusion every 3 to 4 weeks. Daily supplementation with 500 mg calcium and 400 IU vitamin D is recommended. Consider that treatment effects begin after 2-3 months.
• Paget's disease: A single 5 mg intravenous infusion over at least 15 minutes. Daily calcium and vitamin D supplementation is recommended.
• Zometa should be administered by healthcare professionals experienced in intravenous bisphosphonates.
• The infusion must not be mixed with solutions containing divalent cations, such as calcium or lactated Ringer's.
• Ensure adequate hydration before and after administration.

Drug Interactions

• Because Zometa is eliminated through the kidneys, combining it with other potentially nephrotoxic medicines may increase kidney injury risk. Particular caution is needed with aminoglycoside antibiotics such as gentamicin or amikacin, nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or diclofenac, and diuretics, particularly loop diuretics such as furosemide.
• Zometa may lower blood calcium. Other calcium-lowering medicines may increase the risk of hypocalcemia, especially in vitamin D deficiency. Magnesium and phosphate may also decrease, so medicines affecting these minerals require caution.
• Because Zometa is eliminated in urine, combining it with diuretics may increase dehydration and electrolyte imbalance, potentially leading to abnormal heart rhythms.
• Chemotherapy may make Zometa's adverse reactions more pronounced, particularly kidney injury and reduced blood counts. Closer monitoring is therefore required during combined use.
• Aminoglycosides can damage both the kidneys and auditory nerve. Because Zometa may rarely cause hearing problems, combined use may increase ototoxicity risk.
• Combining it with certain medicines for multiple myeloma, such as thalidomide, may increase blood clot or nerve injury risk. Such combinations require careful assessment.

Precautions

• Kidney function: Renal health is important because Zometa is eliminated through the kidneys. Tests such as creatinine should be checked regularly before and during treatment. In kidney impairment, dose adjustment or treatment postponement may be necessary.
• Calcium and vitamin D: Zometa may lower calcium by increasing its withdrawal from bone. Because hypocalcemia is a risk, calcium and vitamin D should be monitored before and during treatment, with supplements if needed.
• Oral and dental health: Bisphosphonates may rarely cause jaw osteonecrosis. Where possible, postpone Zometa before invasive dental procedures such as extractions. A dental examination is recommended before treatment.
• Allergic reactions: Reactions may occur after administration. If rash, itching, or breathlessness develops, stop treatment immediately and provide medical care.
• Pregnancy and breastfeeding: Zometa is not recommended during pregnancy or breastfeeding. Patients who are pregnant or planning pregnancy should not use it because of potential fetal harm. It should also not be used during breastfeeding because passage into breast milk is not fully understood.
• Hydration: Dehydration increases kidney injury risk because the drug is eliminated through the kidneys. Ensure adequate fluid intake before and after treatment, with particular caution in patients at risk of dehydration.
• Liver impairment: Zoledronic acid is not metabolized in the liver, so liver impairment generally poses no problem; careful monitoring is nevertheless recommended.
• Older patients: Kidney function may naturally decline with age, so doses and administration intervals should be planned carefully.
• Children: Zometa's safety and effectiveness in children are not fully established. Pediatric use therefore requires a physician's decision.

Adverse Reactions

Very Common (More Than 1 in 10 Patients; ≥10%)

• Fever: A brief, mild fever may occur within the first 24-48 hours after treatment.
• Muscle and joint pain: Transient muscle pain is common, particularly after the first dose.
• Fatigue and weakness: May result from drug-related metabolic changes.
• Low calcium (hypocalcemia): Blood calcium may fall substantially and requires monitoring.

Common (Up to 1 in 10 Patients; 1% to 10%)

• Headache: May be mild to moderate.
• Nausea and vomiting: May occur particularly after the first infusion.
• Diarrhea or constipation: Some patients experience gastrointestinal changes.
• Flu-like symptoms: May include chills, weakness, muscle pain, or sore throat.
• Loss of appetite: May occur particularly during prolonged treatment.
• Uncommon (Up to 1 in 100 Patients; 0.1% to 1%)
• Skin rash and itching: May indicate a mild allergic reaction.
• Low blood pressure: May rarely occur during infusion.
• Dry mouth and taste changes: May be temporary.
• Numbness or tingling in the hands and feet: A rare nervous system adverse reaction.

Rare (Fewer Than 1 in 1000 Patients; 0.01% to 0.1%)

• Osteonecrosis of the jaw (bone tissue destruction): Risk increases particularly with prolonged use and after tooth extraction.
• Eye inflammation (uveitis, scleritis): May present with redness, pain, and blurred vision.
• Kidney dysfunction: May develop after high doses or rapid administration, making infusion duration and hydration important.